NCT02632409 · OUTCOME

Overall Survival in Participants With PD-L1 Expression ≥ 1%

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer · Source last updated 2026-07-30

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: on going

What was measured

the time from randomization to the date of death from any cause.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-05
denom Units Selected: Participants
description: the time from randomization to the date of death from any cause.
reporting Status: NOT_POSTED
time Frame: on going
title: Overall Survival in Participants With PD-L1 Expression ≥ 1%
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice